Seller record · maximustribe.com

Maximus

Recorded September 2026 · Standard v1.1

Fails 2 of 8 criteria. S3, pharmacy identification: Nine pages were read, covering the terms, privacy, about, contact and treatment surfaces, and the about page heads a section on selecting pharmacy partners without naming one. 1 more criterion also fails; see the table below.

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A performance-medicine telehealth service selling compounded semaglutide and tirzepatide beside brand GLP-1 pens and tablets. It states that it runs its own clinical studies and publishes the results.

Operating entity Maximus Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	maximustribe.com/about-us
S2	Prescription gating	PASS	app.maximustribe.com/weight-loss-start
S3	Pharmacy identification	FAIL	maximustribe.com/about-us
S4	Compounding disclosure	PASS	maximustribe.com/weight-loss/semaglutide-standard
S5	Analytical documentation	FAIL	maximustribe.com/weight-loss
S6	Business address	PASS	maximustribe.com/terms-of-use
S7	Price disclosure	PASS	maximustribe.com
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe about page states that board-certified doctors treat each client, and the treatment pages require a medical evaluation before a prescription; no individual prescriber is named.Source: maximustribe.com/about-us.

S2PASSThe order path was walked and reached a guest onboarding intake on the application subdomain, before any payment field.Source: app.maximustribe.com/weight-loss-start.

S3FAILNine pages were read, covering the terms, privacy, about, contact and treatment surfaces, and the about page heads a section on selecting pharmacy partners without naming one.Source: maximustribe.com/about-us.

S4PASSThe semaglutide page states that compounded semaglutide is available by prescription only after medical evaluation and is not Food and Drug Administration approved.Source: maximustribe.com/weight-loss/semaglutide-standard.

S5FAILNine pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure.Source: maximustribe.com/weight-loss.

S6PASSThe terms and the privacy policy both print a street address with a unit number on Main Street in Santa Monica, California, given for written notice.Source: maximustribe.com/terms-of-use.

S7PASSThe homepage prints three starting figures with no account required, at 149.99 dollars, 199.99 dollars and 249.99 dollars, and the intake opens at 179 dollars per month.Source: maximustribe.com.

S8PASSFDA warning letter 730095, June 2026, names Maximus Health, Inc. at the street address this site prints, and cites claims that a compounded product is clinically studied. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo.

Enforcement documents on file: 1 warning letter

FDA warning letter 730095, issued June 2026, to Maximus Health, Inc. dba MaximusClaims on maximustribe.com that its compounded semaglutide and tirzepatide are clinically studied and proven to lose weight are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.